Sartorius Stedim Biotech Statistics

Total Valuation

Sartorius Stedim Biotech has a market cap or net worth of EUR 17.91 billion. The enterprise value is 20.41 billion.

Market Cap	17.91B
Enterprise Value	20.41B

Important Dates

The next estimated earnings date is Thursday, October 17, 2024.

Earnings Date	Oct 17, 2024
Ex-Dividend Date	Apr 2, 2024

Share Statistics

Sartorius Stedim Biotech has 97.31 million shares outstanding. The number of shares has increased by 2.62% in one year.

Shares Outstanding	97.31M
Shares Change (YoY)	+2.62%
Shares Change (QoQ)	+1.07%
Owned by Insiders (%)	0.00%
Owned by Institutions (%)	13.00%
Float	29.47M

Valuation Ratios

The trailing PE ratio is 102.32 and the forward PE ratio is 44.83. Sartorius Stedim Biotech's PEG ratio is 2.12.

PE Ratio	102.32
Forward PE	44.83
PS Ratio	6.31
PB Ratio	4.51
P/FCF Ratio	58.71
PEG Ratio	2.12

Financial Ratio History

Enterprise Valuation

The stock's EV/EBITDA ratio is 30.15, with an EV/FCF ratio of 66.91.

EV / Earnings	120.39
EV / Sales	7.43
EV / EBITDA	30.15
EV / EBIT	48.95
EV / FCF	66.91

Financial Position

The company has a current ratio of 1.94, with a Debt / Equity ratio of 74.38.

Current Ratio	1.94
Quick Ratio	0.95
Debt / Equity	74.38
Debt / EBITDA	4.31
Debt / FCF	9.57
Interest Coverage	2.47

Financial Efficiency

Return on equity (ROE) is 5.31% and return on invested capital (ROIC) is 4.82%.

Return on Equity (ROE)	5.31%
Return on Assets (ROA)	3.93%
Return on Capital (ROIC)	4.82%
Revenue Per Employee	264,583
Profits Per Employee	16,326
Employee Count	10,382
Asset Turnover	0.41
Inventory Turnover	1.71

Taxes

Income Tax	n/a
Effective Tax Rate	n/a

Stock Price Statistics

The stock price has decreased by -88.43% in the last 52 weeks. The beta is 0.66, so Sartorius Stedim Biotech's price volatility has been lower than the market average.

Beta (5Y)	0.66
52-Week Price Change	-88.43%
50-Day Moving Average	167.93
200-Day Moving Average	211.32
Relative Strength Index (RSI)	63.70
Average Volume (20 Days)	46,738

Short Selling Information

Short Interest	n/a
Short Previous Month	n/a
Short % of Shares Out	n/a
Short % of Float	n/a
Short Ratio (days to cover)	n/a

Income Statement

In the last 12 months, Sartorius Stedim Biotech had revenue of EUR 2.75 billion and earned 169.50 million in profits. Earnings per share was 1.80.

Revenue	2.75B
Gross Profit	1.19B
Operating Income	416.90M
Pretax Income	236.40M
Net Income	169.50M
EBITDA	651.90M
EBIT	416.90M
Earnings Per Share (EPS)	1.80

Full Income Statement

Balance Sheet

The company has 454.10 million in cash and 2.92 billion in debt, giving a net cash position of -2.46 billion or -25.33 per share.

Cash & Cash Equivalents	454.10M
Total Debt	2.92B
Net Cash	-2.46B
Net Cash Per Share	-25.33
Equity (Book Value)	3.92B
Book Value Per Share	40.84
Working Capital	823.80M

Full Balance Sheet

Cash Flow

In the last 12 months, operating cash flow was 706.10 million and capital expenditures -401.10 million, giving a free cash flow of 305.00 million.

Operating Cash Flow	706.10M
Capital Expenditures	-401.10M
Free Cash Flow	305.00M
FCF Per Share	3.13

Full Cash Flow Statement

Margins

Gross margin is 43.16%, with operating and profit margins of 15.18% and 6.17%.

Gross Margin	43.16%
Operating Margin	15.18%
Pretax Margin	8.61%
Profit Margin	6.17%
EBITDA Margin	23.73%
EBIT Margin	15.18%
FCF Margin	11.10%

Dividends & Yields

This stock pays an annual dividend of 0.69, which amounts to a dividend yield of 0.38%.

Dividend Per Share	0.69
Dividend Yield	0.38%
Dividend Growth (YoY)	-52.08%
Years of Dividend Growth	3
Payout Ratio	39.59%
Buyback Yield	-2.62%
Shareholder Yield	-2.24%
Earnings Yield	0.98%
FCF Yield	1.70%

Dividend Details

Stock Splits

The last stock split was on May 6, 2016. It was a forward split with a ratio of 6.

Last Split Date	May 6, 2016
Split Type	Forward
Split Ratio	6